Drug Type Radiolabeled antibody, Therapeutic radiopharmaceuticals |
Synonyms DEP HER2-lutetium, DEP-HER2-lutetium 177, DEP® HER2-lutetium |
Target |
Action modulators |
Mechanism HER2 modulators(Receptor tyrosine-protein kinase erbB-2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | United States | 28 Jan 2022 |